Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by Kewl2on Sep 07, 2012 12:08pm
206 Views
Post# 20332549

RE: RE: Why?

RE: RE: Why?

Important to remember that the timing and the content of the PR are controlled by Aurizon.

 

The choice of "cutoff grade" and "capping grade" are directly reflected in the amount of $$$ that they will need to pay NOX at the end of the this years drill campaign based on final resource estimate.

 

This N43-101 included the 1st year's drill program - it does not include the incredible assay results received over the past 12 months during the 2nd year campaign - and - the "capping" reduced this report by high percentages (-19% M&I and -60% inferred).

 

IF AurizonvIS going to make an offer to buy Niogold - I would think that it would happen soon ---> while shareholders may think we "only" have 1.5M ounces and thus be willing to accept a lower takeover offer.

 

SO -- add in last years drilling --- lower the cutoff grade to reflect $1700 POG  -- remove the 25g/t cap (this is an open pit scenario - it ALL gets mined) --> I would not be surprised to discover that we are already at 2.5-3M oz -- double the resource estimate released today.

 

So why is the SP down on such an excellent report ----> some may be buy the rumour sell the news but I ask myself -- whose "interest is it in" to keep the SP under control?

<< Previous
Bullboard Posts
Next >>